ELI LILLY & CO COM (LLY) : Asymmetry Capital Management added new position in ELI LILLY & CO COM during the most recent quarter end. The investment management firm now holds 65,400 shares of ELI LILLY & CO COM which is valued at $5,090,082 , the company said in a statement filed on Apr 21, 2016 with the SEC.ELI LILLY & CO COM makes up approximately 12.03% of Asymmetry Capital Management’s portfolio.
ELI LILLY & CO COM opened for trading at $76.52 and hit $77.16 on the upside on Wednesday, eventually ending the session at $76.51, with a gain of 0.31% or 0.24 points. The heightened volatility saw the trading volume jump to 36,90,949 shares. Company has a market cap of $84,627 M.
Other Hedge Funds, Including , Advisory Services Network boosted its stake in LLY in the latest quarter, The investment management firm added 3,838 additional shares and now holds a total of 15,483 shares of ELI LILLY & CO COM which is valued at $1,205,042. ELI LILLY & CO COM makes up approx 0.32% of Advisory Services Network’s portfolio.Gulf International Bank (uk) Ltd boosted its stake in LLY in the latest quarter, The investment management firm added 2,240 additional shares and now holds a total of 298,636 shares of ELI LILLY & CO COM which is valued at $23,242,840. ELI LILLY & CO COM makes up approx 0.39% of Gulf International Bank (uk) Ltd’s portfolio.Blue Fin Capital reduced its stake in LLY by selling 1,705 shares or 11.08% in the most recent quarter. The Hedge Fund company now holds 13,684 shares of LLY which is valued at $1,033,553. ELI LILLY & CO COM makes up approx 0.87% of Blue Fin Capital’s portfolio.Edge Wealth Management reduced its stake in LLY by selling 50 shares or 8.2% in the most recent quarter. The Hedge Fund company now holds 560 shares of LLY which is valued at $41,412. ELI LILLY & CO COM makes up approx 0.02% of Edge Wealth Management’s portfolio.
On the company’s financial health, ELI LILLY & CO COM reported $0.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $4865.10 million for the quarter, compared to analysts expectations of $4829.37 million. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.
Many Wall Street Analysts have commented on ELI LILLY & CO COM. Societe Generale Initiated ELI LILLY & CO COM on Apr 6, 2016 to “Hold”, Price Target of the shares are set at $78.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.